Patent application number | Description | Published |
20100008975 | Predicting response to a HER inhibitor - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 01-14-2010 |
20100112603 | METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT - The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed. | 05-06-2010 |
20100279431 | USE OF BNP-TYPE PEPTIDES FOR PREDICTING DIALYSIS NEED - The present invention relates to diagnosing the risk of developing a need for dialysis and/or predicting a need for dialysis, particularly in patients suffering from renal disorders, comprising the steps of measuring the level of a BNP-type peptide or a variant thereof in a sample from the patient, diagnosing the risk by comparing the measured level of the BNP-type peptide or a variant thereof to at least one reference level. The BNP-type peptide may, for example, be brain natriuretic peptide (BNP), proBNP, NT-proBNP, a variant of BNP, a variant of proBNP, or a variant of NT-proBNP. | 11-04-2010 |
20110245103 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
20110246399 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
20130039909 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 02-14-2013 |
20150111211 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 04-23-2015 |